Screener
Syndax Pharmaceuticals SNDX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by investing activities | 38,390 | 94,142 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from Employee Stock Purchase Plan | 458 | 545 |
| Proceeds from stock option exercises | 7,460 | 385 |
| Net cash provided by financing activities | 7,918 | 930 |
| NET DECREASE CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (4,037) | (90) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period | 135,032 | 154,300 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —end of period | $130,995 | $154,210 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's net change in cash?
- Syndax Pharmaceuticals (SNDX) reported net change in cash of -$4.04M in Q1 2026.
- How has Syndax Pharmaceuticals's net change in cash changed year-over-year?
- Syndax Pharmaceuticals's net change in cash decreased by 4385.6% year-over-year, from -$90K to -$4.04M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Syndax Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude